FDA Clears Key Chemiluminescent Assays for Autoimmune Diagnostics
By LabMedica International staff writers Posted on 16 Aug 2015 |
The US Food and Drug Administration (FDA) has cleared for use on the Bio-Flash automated platform several assays for connective tissue diseases (CTDs) and one assay for a novel antiphospholipid syndrome (APS) biomarker.
Inova Diagnostics (San Diego, CA, USA), a leader in autoimmune diagnostics to enhance patient care, has received 510(k) clearance on key “QUANTA Flash” assays for use with the “BIO-FLASH” chemiluminescent analyzer for autoimmune testing. QUANTA Flash extractable nuclear antigen (ENA) assays are used to aid in the diagnosis of CTDs such as Systemic Lupus Erythematosus, Sjogren's Syndrome, and Systemic Sclerosis. The new clearance adds QUANTA Flash Ro60, Ro52, and SSB to the menu previously FDA-cleared ENA assays, including QUANTA Flash Sm, RNP, Centromere, and ENA7 assays.
In addition, Inova received clearance of QUANTA Flash Beta-2 Glycoprotein1 Domain1 (Beta-2GP1 Domain1), a novel, highly specific marker that, in conjunction with clinical and other laboratory findings, aids in the diagnosis of APS. The assay is not intended to replace tests for antibodies against the whole Beta-2GP1 molecule. Testing for antibodies to the whole Beta-2GP1 molecule is required according to the APS classification criteria. "Since the discovery of this disease by Prof. Graham Hughes in 1983, numerous breakthroughs have helped save lives and reduce childbirth complications for those suffering from APS. This latest breakthrough in the availability of a test for Domain 1 will help doctors identify those patients who need the most critical care and are at greatest risk of thrombotic events such as stroke," said Prof. Munther Khamashta, Rayne Institute, St. Thomas' Hospital (London, UK). Roger Ingles, CEO, Inova Diagnostics, said, “The addition of QUANTA Flash Beta-2GP1 Domain1 to the BIO-FLASH menu provides a novel marker to support patient care in a very challenging disease.”
QUANTA Flash now includes 22 FDA-cleared and 29 CE-marked tests available on the BIO-FLASH platform. In addition to ENA and APS assays, the menu for BIO-FLASH also includes tests for celiac disease and vasculitis. "The announced FDA clearance for these assays means that clinical laboratories can now take advantage of the benefits of this powerful system. We have had BIO-FLASH running in our lab for over 10 months. We are very satisfied with the performance, as it allows us to run these markers more efficiently," said Claudia Ibarra, vice president of Laboratory Operations at Thierry Dervieux, and chief scientific officer at Exagen Diagnostics.
BIO-FLASH is an automated, random-access chemiluminescent instrument that delivers results in as little as 30 minutes. It offers the autoimmune clinical laboratory a wide analytical measuring range for handling routine, specialized, and STAT immunology tests in-house with greater speed and precision. "We are excited about providing customers with a greatly expanded menu on BIO-FLASH. The random-access capabilities of BIO-FLASH delivers enhanced workflow efficiencies and improves turn-around time, making even the most specialized autoimmune tests efficient to perform," said Mr. Ingles.
Related Links:
Inova Diagnostics
Inova Diagnostics (San Diego, CA, USA), a leader in autoimmune diagnostics to enhance patient care, has received 510(k) clearance on key “QUANTA Flash” assays for use with the “BIO-FLASH” chemiluminescent analyzer for autoimmune testing. QUANTA Flash extractable nuclear antigen (ENA) assays are used to aid in the diagnosis of CTDs such as Systemic Lupus Erythematosus, Sjogren's Syndrome, and Systemic Sclerosis. The new clearance adds QUANTA Flash Ro60, Ro52, and SSB to the menu previously FDA-cleared ENA assays, including QUANTA Flash Sm, RNP, Centromere, and ENA7 assays.
In addition, Inova received clearance of QUANTA Flash Beta-2 Glycoprotein1 Domain1 (Beta-2GP1 Domain1), a novel, highly specific marker that, in conjunction with clinical and other laboratory findings, aids in the diagnosis of APS. The assay is not intended to replace tests for antibodies against the whole Beta-2GP1 molecule. Testing for antibodies to the whole Beta-2GP1 molecule is required according to the APS classification criteria. "Since the discovery of this disease by Prof. Graham Hughes in 1983, numerous breakthroughs have helped save lives and reduce childbirth complications for those suffering from APS. This latest breakthrough in the availability of a test for Domain 1 will help doctors identify those patients who need the most critical care and are at greatest risk of thrombotic events such as stroke," said Prof. Munther Khamashta, Rayne Institute, St. Thomas' Hospital (London, UK). Roger Ingles, CEO, Inova Diagnostics, said, “The addition of QUANTA Flash Beta-2GP1 Domain1 to the BIO-FLASH menu provides a novel marker to support patient care in a very challenging disease.”
QUANTA Flash now includes 22 FDA-cleared and 29 CE-marked tests available on the BIO-FLASH platform. In addition to ENA and APS assays, the menu for BIO-FLASH also includes tests for celiac disease and vasculitis. "The announced FDA clearance for these assays means that clinical laboratories can now take advantage of the benefits of this powerful system. We have had BIO-FLASH running in our lab for over 10 months. We are very satisfied with the performance, as it allows us to run these markers more efficiently," said Claudia Ibarra, vice president of Laboratory Operations at Thierry Dervieux, and chief scientific officer at Exagen Diagnostics.
BIO-FLASH is an automated, random-access chemiluminescent instrument that delivers results in as little as 30 minutes. It offers the autoimmune clinical laboratory a wide analytical measuring range for handling routine, specialized, and STAT immunology tests in-house with greater speed and precision. "We are excited about providing customers with a greatly expanded menu on BIO-FLASH. The random-access capabilities of BIO-FLASH delivers enhanced workflow efficiencies and improves turn-around time, making even the most specialized autoimmune tests efficient to perform," said Mr. Ingles.
Related Links:
Inova Diagnostics
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Immunology News
- Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients
- Biomarker Could Predict Immunotherapy Response in Liver Cancer
- Epigenetic Test Could Determine Efficacy of New Immunotherapy Treatments Against Multiple Myeloma
- Blood Test Predicts Survival in Liver Cancer Patients
- Simple Blood Test Identifies Multiple Myeloma Patients Likely to Benefit from CAR-T Immunotherapy
- Portable Device Analyzes White Blood Cell Activity to Monitor Cancer Patients’ Health
- New Test Detects Return of Blood Cancer a Year Earlier
- Universal Blood Test Could Predict Organ Transplant Outcomes with Unprecedented Accuracy
- AI Tool Predicts Cancer Patients’ Response to Immunotherapy
- Molecular Profiling Improves Diagnosis for Children with High Risk Cancers
- Blood Test Measures Immune Response to Epstein-Barr Virus in MS Patients
- AI Predicts Tumor-Killing Cells with High Accuracy
- Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies
- AI Tool Precisely Matches Cancer Drugs to Patients Using Information from Each Tumor Cell
- Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment
- Testing Method Could Help More Patients Receive Right Cancer Treatment